Oncoustics AI
Komathi Stem is a seasoned professional with extensive experience in the healthcare and biotechnology sectors. Currently serving as a Strategic Advisor at Oncoustics since June 2021, Komathi provides strategic guidance for the development of AI/ML solutions in point-of-care diagnostics. As the Chief Executive Officer of ReThynk Consulting since February 2016, and a Board Member at CoPeace since September 2018, Komathi's leadership spans across various organizations. Previous roles include Chief Operating Officer at Glooko and Founder and CEO of monARC Bionetworks, Inc., focusing on democratizing research and accelerating drug discovery. Notable experience at Genentech involved positions such as Strategic Innovation Consultant and Senior Director of Product Development, along with leadership roles at Science 37, Inc., AstraZeneca, and Eli Lilly and Company. Komathi holds a Master's degree in Biomedical/Medical Engineering and a Bachelor's degree in Mathematics from the University of Virginia and St. Olaf College, respectively.
This person is not in any teams
This person is not in any offices
Oncoustics AI
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.